NCT06568861

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

← 임상시험 허브

레지스트리 요약

진행 상태: 완료 (COMPLETED)
질환/조건: COVID-19
시험 유형: 중재 연구 (INTERVENTIONAL)
단계: Phase 1
목적: 치료
중재 유형: 약물
개입·치료: ALG-097558
Lead Sponsor: Aligos Therapeutics (산업계)

캐시 시각: 2026-08-06 08:28:28

ClinicalTrials.gov에서 보기

요약

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.

리포트 문의 메디컬라이팅 문의 맞춤 리서치 리포트